
Zvolte si etiketu
zobrazeno přímo na lahvičceReta + Tesamorelin Blend
GLP-1
- Odesíláme z Německa
Objednávka
- DHL se sledováním zásilky
- Diskrétní balení
V kostce
Reta + Tesamorelin Blend v číslech
Klíčové údaje z našeho lexikonu.
Celé heslo v lexikonu- Type
- Injectable blendtriple agonist + GHRH analog
- Sizes
- 20 mg1 size in the shop
What studies show
All 4 sources in the lexiconRetatrutide phase 2 trial (obesity), 48 weeks, NEJM 2023 (opens in a new tab)
New England Journal of Medicine (PubMed PMID 37366315)Retatrutide systematic review + meta-analysis (878 patients), 2025 (opens in a new tab)
Proc (Bayl Univ Med Cent) (PubMed PMID 40291085)Tesamorelin phase 3 trial (visceral fat, HIV), 12 months (opens in a new tab)
J Acquir Immune Defic Syndr (PubMed PMID 20101189)
Hodnocení
Co říkají zákazníci
Jen skutečné objednávky, které obsahovaly Reta + Tesamorelin Blend.
Všechna hodnoceníPro Reta + Tesamorelin Blend zatím neexistuje laboratorní analýza. Hlasujte pro toNechte si to otestovat sami, polovinu zaplatímeVšechny laboratorní analýzy
Znalosti
Vše o Reta + Tesamorelin Blend
Podrobné informace připravujeme.
Dávkování
Načítání informací o dávkování …
Hodí se přiobjednat
Co k tomu potřebujete
Bakteriostatická voda se do košíku přidá automaticky. Stříkačky a tampony jedním kliknutím.
Inzulinové stříkačky
10 ks · 5.50 €
Alkoholové tampony
50 ks · 10 €
Kolik vody?
Jednotky na stříkačce pro vaši velikost lahvičky.
Otevřít kalkulačku →Is the Reta + Tesamorelin Blend approved or studied?
No. As of 26 October 2026 the registry ClinicalTrials.gov lists no trial with Retatrutide and tesamorelin together. Tesamorelin alone has been approved in the USA since 2010, Retatrutide is in phase 3 and not approved.
What is the catch with the fixed mix?
The two substances were studied on very different schedules: Retatrutide once a week, tesamorelin daily. In a 1:1 vial the ranges from both trial programmes cannot be matched at the same time. The entry therefore goes by the Retatrutide share.
What do the Retatrutide trials show?
In phase 2 body weight fell by 24.2 percent after 48 weeks at the highest study dose, by 2.1 percent on placebo. In phase 3 (TRIUMPH-1) it was 25.0 versus 3.9 percent after 80 weeks. A meta-analysis with 878 participants confirmed clear effects on weight and metabolic values.
What do the tesamorelin trials show?
In 806 patients with HIV and excess belly fat, visceral fat fell by 15.4 percent more than on placebo in 26 weeks, subcutaneous fat stayed nearly the same. IGF-1 rose, blood sugar stayed stable. Those who continued kept the effect to week 52.
Which side effects were seen with the components?
Retatrutide: mainly nausea, diarrhoea and other gastrointestinal effects, depending on the dose, plus a slight rise in heart rate. Tesamorelin: injection site reactions, joint and muscle pain, fluid retention and tingling. There is no safety profile for the blend.
Which trials are still running?
Nine phase 3 trials of Retatrutide are running, the largest on heart and kidney events until 2029. The phase 3 trials of tesamorelin were completed years ago. No trial of the blend is listed in the registry.
Související
Související produkty
Tirzepatide
Peptidy · GLP-1 a hubnutí GLP-1 a hubnutí
10 velikosti
Laboratorně testováno
= od 10 €/lahvička
Retatrutide
Peptidy · GLP-1 a hubnutí GLP-1 a hubnutí
11 velikosti
Laboratorně testováno
= od 16 €/lahvička
Semaglutide
Peptidy · GLP-1 a hubnutí GLP-1 a hubnutí
6 velikosti
Laboratorně testováno
= od 10 €/lahvička
Mazdutide
Peptidy · GLP-1 a hubnutí GLP-1 a hubnutí
2 velikosti
= od 32 €/lahvička
Reta + Tesamorelin Blend